Neurotech Industry 2016-2017 Report
More than 500 profiles of public and private neurotech companies including drugs, devices and diagnostics
Pipelines and market analysis for 20 brain and nervous system illnesses including: addiction, Alzheimer's disease, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, mild cognitive impairment, migraine, multiple sclerosis, obesity, pain, Parkinson's disease, retinal disorders, schizophrenia, stroke, and traumatic brain injury
Top neurotech investors, venture capital firms, and venture capital trends
Neurotech IPOs, M&A, Partnering and Licensing deals and public neurotech stock performance
Analysis of biological basis, current treatment options, and emerging therapeutic strategies
Analysis of compounds, cell therapies and devices in clinical trials (and abandoned) by company, mechanism of action and stage of development for each indication
Global and US market size, worldwide revenues for each indication
Extensive discussion of specific technological, demographic, regulatory and intellectual property trends
Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets.
Now in its 12th year, The Neurotechnology Industry 2016-2017 Report is an expanded and updated 650 page report of brain and nervous system markets and treatments. It is the only publication to provide a comprehensive pipeline and market analysis to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets.
The report includes detailed information on products in development globally for over 20 indications at 800 companies including Alzheimer's, addiction, ALS, anxiety, depressive disorders, epilepsy, migraine, mild cognitive impairment, Huntington's, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, traumatic brain injury and stroke.